Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193803 | 0.89 | HRH3 (0.59) | ALDH1A1SMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL12804795 | 0.88 | CD274 (0.48) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPK1 | |
| SCHEMBL10174114 | 0.85 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KMT2AKDM4EGAA | |
| SCHEMBL10193853 | 0.84 | GAA (0.46) | ALDH1A1SMN1; SMN2KDM4EGAAATM | |
| SCHEMBL15426234 | 0.84 | GAA (0.46) | ALDH1A1SMN1; SMN2KDM4EGAAATM | |
| SCHEMBL10174122 | 0.82 | POLB (0.52) | ALDH1A1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL10174139 | 0.82 | GAA (0.44) | ALDH1A1SMN1; SMN2KDM4EGAAATM | |
| SCHEMBL17482090 | 0.82 | GAA (0.44) | ALDH1A1SMN1; SMN2KDM4EGAAATM | |
| SCHEMBL10174128 | 0.78 | EPHX2 (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL5089275 | 0.78 | PIK3CA (0.67) | ALDH1A1SMN1; SMN2RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | ARISAPH PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | ARISAPH PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9212142-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212142-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150094303-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE | 2015-04-02 | — | — | US | disclosed |
| US-20150094303-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE | 2015-04-02 | — | — | US | disclosed |
| US-8937063-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937063-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | Arisaph Pharmaceuticals (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | Arisaph Pharmaceuticals (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450316-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450316-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120077808-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077808-A1 | Niacin Mimetics, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2011163619-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094303-A1 | Niacin Mimetics, and Methods of Use Thereof | NAMPT, NADK, NAPRT | ALDH1A1 772/4885SMN1; SMN2 860/4885RAB9A 1743/4885 |
| US-20160030441-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | NAMPT, NNT, NAPRT | ALDH1A1 564/4885SMN1; SMN2 492/4885RAB9A 1884/4885 |
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | NAMPT, NNT, NAPRT | ALDH1A1 564/4885SMN1; SMN2 492/4885RAB9A 1884/4885 |
| US-20120077808-A1 | Niacin Mimetics, and Methods of Use Thereof | NAMPT, NADK, NAPRT | ALDH1A1 772/4885SMN1; SMN2 860/4885RAB9A 1743/4885 |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | NAMPT, NNT, NAPRT | ALDH1A1 564/4885SMN1; SMN2 492/4885RAB9A 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.